Boardroom Alpha
Boardroom Alpha
LMAT · Current Report (Form 8-K) · Filed June 3, 2025

Lemaitre Vascular Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 3, 2025
Period
Jun 2, 2025
Ticker
LMAT
Accession
0001437749-25-019314
Boardroom Alpha · Filing insights

Stockholders elected three Class I directors, approved executive compensation, set 1-year frequency for Say-on-Pay, and ratified Grant Thornton.

About Lemaitre Vascular Inc
Market cap
$2.1B
1Y TSR
+23.3%
3Y TSR
+16.1%
Board grade
A-
Sector
Healthcare
CEO
George W Lemaitre
Last annual meeting: Jun 2, 2026 · View full Lemaitre Vascular Inc profile →
lmat20250603_8k.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 

 
FORM 8-K
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(0) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): June 2, 2025
 

 
LeMaitre Vascular, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 

 
Delaware
(State or Other Jurisdiction of Incorporation)
 
 
001-33092 04-2825458
(Commission File Number) (IRS Employer Identification No.)
   
63 Second Avenue 01803
Burlington, Massachusetts (Zip Code)
(Address of Principal Executive Offices)  
 
 
(781) 221-2266
(Registrant's Telephone Number, Including Area Code)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common
LMAT
The Nasdaq Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. D
 
 

 
Item 5.07. Submission of Matters to a Vote of Security Holders.
 
(a)      On June 2, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 22,594,362 shares of the Company's common stock were entitled to vote as of April 8, 2025, the record date for the Annual Meeting, of which 21,068,573 shares were present in person or represented by proxy at the Annual Meeting.
 
(b)      Matters voted upon by the stockholders at the Annual Meeting were: (i) the election of three Class I directors nominated by the Board of Directors for three-year terms; (ii) an advisory vote on the compensation of the Company's named executive officers; (iii) an advisory vote on the frequency of future advisory votes on executive compensation; and (iv) the ratification of the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for 2025.
 
Set forth below is information concerning each matter submitted to a vote at the Annual Meeting.
 
Proposal No.1 Election of Directors
 
By a majority of votes cast, the stockholders elected the following three nominees as Class I directors for a term of three years expiring upon the 2028 Annual Meeting of Stockholders or until their successor has been duly elected and qualified. George W. LeMaitre received a vote of 18,389,000.35701 shares for, 1,621,733 shares withheld and 1,057,839 broker non-votes. David B. Roberts received a vote of 18,223,556 shares for, 1,787,178 shares withheld and 1,057,839 broker non-votes. Martha Shadan received a vote of 15,217,924 shares for, 4,792,810 shares withheld and 1,057,839 broker non-votes.
 
Proposal No. 2 Advisory Vote on Executive Compensation
 
By a majority of votes cast, the stockholders approved, on an advisory basis, the Company's executive compensation by a vote of 19,060,967 shares for and 913,117 shares against, 36,649 shares abstaining, and 1,057,839 broker non-votes.
 
Proposal No.3 Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation
 
By a majority of votes cast, the stockholders approved, on an advisory basis, a frequency of “1 Year” for future advisory votes on executive compensation by a vote of:
 
1 Year:
16,990,007     
2 Years:
18,302     
3 Years:
2,972,329     
Abstain:
30,096     
 
 
Proposal No.4 Ratification of the Selection of Independent Registered Public Accounting Firm
 
By a majority of votes cast, the stockholders ratified the selection of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025, with a vote of 21,006,527 shares for, 43,143 shares against, and 18,903 shares abstaining.
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: June 3, 2025
LEMAITRE VASCULAR, INC.
By:
/s/ Dorian P. LeBlanc
Name:      Dorian P. LeBlanc
Title:        Chief Financial Officer
 
 
 
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Lemaitre Vascular Inc (LMAT)

Reference

Frequently asked questions

When did Lemaitre Vascular Inc file this 8-K?
Lemaitre Vascular Inc (LMAT) filed this Current Report (Form 8-K) with the SEC on June 3, 2025. The accession number assigned by EDGAR is 0001437749-25-019314.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders elected three Class I directors, approved executive compensation, set 1-year frequency for Say-on-Pay, and ratified Grant Thornton. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Lemaitre Vascular Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Lemaitre Vascular Inc has filed under CIK 1158895, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer